[go: up one dir, main page]

DK3523274T3 - Formuleringer til indgivelse af eflornithin - Google Patents

Formuleringer til indgivelse af eflornithin

Info

Publication number
DK3523274T3
DK3523274T3 DK17858939.6T DK17858939T DK3523274T3 DK 3523274 T3 DK3523274 T3 DK 3523274T3 DK 17858939 T DK17858939 T DK 17858939T DK 3523274 T3 DK3523274 T3 DK 3523274T3
Authority
DK
Denmark
Prior art keywords
eflornithin
formulations
administration
Prior art date
Application number
DK17858939.6T
Other languages
English (en)
Inventor
Noymi Yam
Victor A Levin
Alexander Vakoula
Original Assignee
Orbus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orbus Therapeutics Inc filed Critical Orbus Therapeutics Inc
Application granted granted Critical
Publication of DK3523274T3 publication Critical patent/DK3523274T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00Preparation of sulfones; Preparation of sulfoxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK17858939.6T 2016-10-06 2017-09-29 Formuleringer til indgivelse af eflornithin DK3523274T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662404981P 2016-10-06 2016-10-06
PCT/US2017/054450 WO2018067401A1 (en) 2016-10-06 2017-09-29 Formulations for administration of eflornithine

Publications (1)

Publication Number Publication Date
DK3523274T3 true DK3523274T3 (da) 2025-11-17

Family

ID=61831551

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17858939.6T DK3523274T3 (da) 2016-10-06 2017-09-29 Formuleringer til indgivelse af eflornithin

Country Status (12)

Country Link
US (3) US10786470B2 (da)
EP (1) EP3523274B1 (da)
JP (3) JP7262118B2 (da)
KR (2) KR102592801B1 (da)
CN (2) CN110191876A (da)
AU (2) AU2017339781B2 (da)
CA (2) CA3176428A1 (da)
DK (1) DK3523274T3 (da)
IL (2) IL314380A (da)
MX (1) MX390145B (da)
NZ (2) NZ752894A (da)
WO (1) WO2018067401A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018067401A1 (en) 2016-10-06 2018-04-12 Orbus Therapeutics, Inc. Formulations for administration of eflornithine
US11918684B2 (en) 2017-03-13 2024-03-05 Liqmeds Worldwide Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
WO2019038584A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
HUE059330T2 (hu) 2018-03-08 2022-11-28 Applied Molecular Transport Inc Toxinból származó bejuttatási konstrukciók orális beadásra
GB2591396B (en) 2018-08-18 2023-06-07 Ftf Pharma Private Ltd Pharmaceutical suspension for oral dosage
EP3836899A2 (en) * 2018-08-18 2021-06-23 FTF Pharma Private Limited Chemotherapeutic pharmaceutical suspension for oral dosage
CN109528667A (zh) * 2018-12-19 2019-03-29 石家庄海瑞药物科技有限公司 一种达克替尼药物组合物及其制备方法
PH12022550330A1 (en) 2019-08-16 2023-02-06 Applied Molecular Transport Inc Compositions, formulations, and interleukin production and purification
WO2021191928A1 (en) * 2020-03-23 2021-09-30 Navin Saxena Research & Technology Pvt. Ltd. Eflornithine composition and dosage forms for the treatment of viral infection
EP4665325A1 (en) * 2023-02-17 2025-12-24 Orbus Therapeutics, Inc. Compositions and methods of using eflornithine

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614557A (en) 1977-07-11 1997-03-25 Marion Merrell Et Compagnie C/O Merrell Pharmaceuticals Inc. Method of controlling tumor growth rate
US4330559A (en) * 1977-07-11 1982-05-18 Merrell-Toraude Et Cie Method of treating benign prostatic hypertrophy
US5002879A (en) 1986-05-06 1991-03-26 Merrell Dow Pharmaceuticals Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor
US5558071A (en) * 1994-03-07 1996-09-24 Combustion Electromagnetics, Inc. Ignition system power converter and controller
US5851537A (en) 1996-02-02 1998-12-22 Cancer Technologies, Inc. Topical application of α-DFMO for preventing skin cancer
DE69724095T2 (de) * 1996-10-04 2004-05-27 Ilex Oncology, Inc., San Antonio DFMO und Taxol zur Behandlung bzw. Vorbeugung von Brustkrebs
AU5200098A (en) 1996-11-01 1998-05-29 Ilex Oncology, Inc. Sustained release formulation containing dfmo
US6646149B1 (en) 1997-07-15 2003-11-11 Nicolaas M. J. Vermeulin Polyamine analogues as therapeutic and diagnostic agents
JP2002509884A (ja) 1998-03-28 2002-04-02 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティ・オブ・アリゾナ 癌の化学防御におけるdfmo及びスリンダクの組合せ
US7815937B2 (en) 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
KR20010109275A (ko) 1998-12-23 2001-12-08 로저 에이. 윌리암스 종양치료의 병용치료로서 사이클로옥시게나제-2 억제제와기질 금속단백분해효소 억제제를 사용하는 방법
US6199698B1 (en) * 1999-12-03 2001-03-13 Alusuisse Technology & Management, Ltd. Pharmaceutical packaging with separation means
US6602910B2 (en) * 2000-03-07 2003-08-05 Ilex Oncology, Inc. D-enantiomer of DFMO and methods of use therefor
WO2001068076A2 (en) * 2000-03-07 2001-09-20 Ilex Oncology, Inc. D-enantiomer of dfmo and methods of use thereof for treating cancer
US6630511B2 (en) 2000-08-01 2003-10-07 Rolland F. Hebert Water-soluble salts of 2-difluoromethyl-2,5-diaminopentanoic acid (DFMO)
WO2003015763A1 (en) * 2001-08-13 2003-02-27 Board Of Regents, The University Of Texas System Adjuvant chemotherapy for anaplastic gliomas
JP3981074B2 (ja) * 2001-08-15 2007-09-26 スキンメディカ,インコーポレーテッド オルニチンデカルボキシラーゼインヒビターの毛包輸送のための局所用組成物
US20030053793A1 (en) * 2001-09-20 2003-03-20 Peter Holzmann Analog/digital recording and playback system and related method
US6998502B1 (en) * 2002-09-05 2006-02-14 Sabinsa Corporation Convenient process of manufacture for difluoromethylornithine and related compounds
US6936318B2 (en) * 2003-09-17 2005-08-30 Reynolds Metals Company No tear pharmaceutical pouch
US8673366B2 (en) 2004-06-14 2014-03-18 Kareem I. Batarseh Chemotherapeutic and prophylactic pharmaceutical compositions
SE0401871D0 (sv) 2004-07-15 2004-07-15 Glucogene Medical Hfm Ab New compositions
WO2006108680A2 (en) * 2005-04-15 2006-10-19 Biomac Privatinstitut Für Medizinische Und Zahnmedizinische Forschung, Entwicklung Und Diagnostik Gmbh Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use against protozoa and helminthes
BRPI0612138B8 (pt) 2005-06-15 2021-05-25 Cardiome Pharma Corp compostos éter aminocicloexílicos e método para fazer os mesmos
US9072778B2 (en) 2005-12-20 2015-07-07 University Of Hawaii Treatment regimen for N-MYC, c-MYC, and L-MYC amplified and overexpressed tumors
US20070246057A1 (en) * 2006-04-20 2007-10-25 Muller Sigfrid A Ear treatment for excess hair
US8124123B2 (en) * 2007-09-05 2012-02-28 Dow Pharmaceutical Sciences, Inc. Controlled release azithromycin solid dosages forms
WO2010028058A1 (en) 2008-09-02 2010-03-11 Oklahoma Medical Research Foundation 2, 4-disulfonyl pheny tert-butyl nitrone for the treatment of gliomas
EP2607498B1 (en) 2008-09-03 2017-05-03 The Johns Hopkins University Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma
WO2010056919A2 (en) 2008-11-12 2010-05-20 Kyphia Pharmaceuticals, Inc. Eflornithine prodrugs, conjugates and salts, and methods of use thereof
CN101898978A (zh) * 2009-05-31 2010-12-01 徐锋 依氟鸟氨酸前药和偶合物及其使用方法
SG182366A1 (en) 2010-01-05 2012-08-30 Vascular Biogenics Ltd Compositions and methods for treating glioblastoma gbm
WO2013096681A1 (en) 2011-12-22 2013-06-27 Gilead Sciences, Inc. Pyrazolo[1,5-a]pyrimidines as antiviral agents
PT2838900T (pt) 2012-04-17 2019-11-15 Gilead Sciences Inc Compostos e métodos para tratamento antiviral
US20190046484A1 (en) * 2015-02-12 2019-02-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating neuroblastoma
WO2017075576A1 (en) * 2015-10-30 2017-05-04 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
KR20180069068A (ko) 2015-10-30 2018-06-22 캔서 프리벤션 파마수티컬스, 인코포레이티드 에플로르니틴 및 설린닥, 고정된 용량 조합 제제
US20190133985A1 (en) 2016-03-24 2019-05-09 Orbus Therapeutics, Inc. Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas
US20170273926A1 (en) 2016-03-24 2017-09-28 Orbus Therapeutics, Inc. Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas
WO2018067401A1 (en) * 2016-10-06 2018-04-12 Orbus Therapeutics, Inc. Formulations for administration of eflornithine
JP2022532766A (ja) * 2019-05-17 2022-07-19 キャンサー プリベンション ファーマシューティカルズ,インコーポレイテッド 家族性腺腫性ポリポーシスを処置するための方法

Also Published As

Publication number Publication date
KR102473491B1 (ko) 2022-12-05
EP3523274A1 (en) 2019-08-14
CA3176428A1 (en) 2018-04-12
JP2019534265A (ja) 2019-11-28
KR20190084960A (ko) 2019-07-17
US20200138758A1 (en) 2020-05-07
NZ752894A (en) 2023-05-26
MX390145B (es) 2025-03-20
US20210038549A1 (en) 2021-02-11
JP7262118B2 (ja) 2023-04-21
KR20220162869A (ko) 2022-12-08
AU2017339781B2 (en) 2022-03-17
AU2022202162A1 (en) 2022-04-21
IL265856B2 (en) 2024-12-01
MX2019003981A (es) 2019-06-10
JP2024153889A (ja) 2024-10-29
AU2017339781A1 (en) 2019-05-16
CA3038530A1 (en) 2018-04-12
EP3523274A4 (en) 2020-05-13
IL265856B1 (en) 2024-08-01
IL314380A (en) 2024-09-01
CN110191876A (zh) 2019-08-30
US20230338317A1 (en) 2023-10-26
AU2022202162B2 (en) 2024-08-15
KR102592801B1 (ko) 2023-10-20
IL265856A (en) 2019-06-30
US11439612B2 (en) 2022-09-13
JP2023040218A (ja) 2023-03-22
NZ792518A (en) 2023-04-28
CN117530943A (zh) 2024-02-09
JP7539175B2 (ja) 2024-08-23
US10786470B2 (en) 2020-09-29
WO2018067401A1 (en) 2018-04-12
EP3523274B1 (en) 2025-11-05

Similar Documents

Publication Publication Date Title
DK3509581T3 (da) Formuleringer af (r)-2-amino-3-phenylpropylcarbamat
DK3523274T3 (da) Formuleringer til indgivelse af eflornithin
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3463248T3 (da) Anordnnger til anvendelse af lægemiddelanordninger
DK3668851T3 (da) Fremgangsmåde til fremstilling af thiocarbonater
DK3439635T3 (da) Formuleringer til behandling af fast tumor
DK3317400T3 (da) Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3378482T5 (da) Formulering til administration af antitumorlægemiddel
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3481838T3 (da) Nye fremgangsmåder til fremstillingen af oligonukleotider
DK3237045T3 (da) Indretning til indgivelse af lægemidler
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3116491T3 (da) Farmaceutiske sammensætninger af terapeutisk aktive forbindelser
DK3881827T3 (en) Formulering til administration af rna
DK3325080T3 (da) Fremgangsmåder til bedre indgivelse af aktive midler til tumorer
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3474822T3 (da) Formuleringer af brincidofovir
DK3233813T3 (da) Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser
DK3529233T3 (da) Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider
DK3242931T3 (da) Formuleringer til stabilisering af bakteriecelleekstrakter
DK3943070T3 (da) Langtidsvirkende formuleringer af bedaquilin
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
DK3325482T3 (da) Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater